Filing Flows › Standard Biotools (LAB) › Q2 2025
Standard Biotools (LAB) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 15, 2025
Standard Biotools (LAB) reported revenue of $21.8M for the second quarter 2025 (Q2 2025), -3% from a year earlier and -47% from the quarter before. Operating margin was -118.1%, net loss $33.5M (153.7% of revenue).
Standard Biotools, Q2 2025: revenue $21.8M (-3% year over year), operating margin -118.1%, net loss $33.5M, operating cash flow −$20.7M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $21.8M | -47% | -3% |
| Operating profit | −$25.7M | — | — |
| Net earnings | −$33.5M | — | — |
| Operating cash flow | −$20.7M | — | — |
What changed
Revenue was $21.8M in Q2 2025, down 3% year over year and down 47% from the previous quarter. Consumables was the largest line at 48% of revenue. Instruments lost $1.8M year over year (down 26%), 251% of the total change.
Gross margin was 48.8%, up 2.7 points from a year earlier. Operating costs exceeded revenue by $25.7M, an operating margin of -118.1%. Operating expenses fell 11% while revenue fell 3%. The fastest-growing cost line was SG&A (+13%). The quarter ended with a net loss of $33.5M, wider than the previous quarter's $26.0M loss.
Operating cash flow was −$20.7M. Non-cash charges added back $3.2M of depreciation and amortization and $6.4M of share-based compensation. Working capital and other items added $3.2M. Capital expenditures of $1.9M exceeded it, leaving free cash flow of −$22.6M.
Questions
What was Standard Biotools' revenue in the second quarter 2025?
Standard Biotools (LAB) reported revenue of $21.8M for the second quarter 2025 (Q2 2025), -3% from a year earlier and -47% from the quarter before.
Was Standard Biotools profitable in the second quarter 2025?
Operating loss was $25.7M (-118.1% of revenue) and net loss $33.5M.
Source: Standard Biotools 10-Q on SEC EDGAR.